In 2024, Adimab and its partners initiated discovery on 62 new therapeutic programs, bringing the total number of ...

Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the Cullinan Oncology LLC stock. Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target H.C. Wainwright has reaffirmed its ...

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a ...